Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.31 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30313835 | 1.00 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3FFAR1CASR | |
| SCHEMBL25191908 | 0.88 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30313823 | 0.82 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25189425 | 0.82 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25189929 | 0.79 | PARP1 (0.38) | SLC6A2SLC6A4SLC6A3CASR | |
| SCHEMBL501378 | 0.71 | MRGPRX4 (0.41) | — | |
| SCHEMBL18506466 | 0.71 | FFAR1 (0.42) | SLC6A2SLC6A4SLC6A3FFAR1 | |
| SCHEMBL18501545 | 0.71 | FFAR1 (0.42) | SLC6A2SLC6A4SLC6A3FFAR1 | |
| SCHEMBL18490151 | 0.70 | FFAR1 (0.56) | FFAR1 | |
| SCHEMBL18490149 | 0.70 | FFAR1 (0.56) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151037-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151037-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151037-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2023-05-18 | — | — | US | disclosed |
| CN-115867536-A | GPR40 agonists | 卡尔优普公司 | 2023-03-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151037-A1 | GPR40 AGONISTS | GPR119, GPR65, GLP1R | SLC6A2 1148/4885SLC6A4 596/4885SLC6A3 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.